Compare Marsh & McLennan Companies, Inc. (MRSH) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs TG Therapeutics Inc — how do they compare? Marsh & McLennan Companies, Inc. trades at $180.04 (market cap $87.77B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 10.6× TG Therapeutics Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.17% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MRSH | TGTX | |
|---|---|---|
Market Cap | $87.77B | $8.26B |
Sector | Financials | Health |
52-Week High | $211.21 | $59.06 |
52-Week Low | $157.32 | $26.39 |
Enterprise Value | $108.61B | $8.50B |
Dividend Yield | 2.17% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
